Research

Researchers Develop Marburg Virus Treatment Effective Five Days After Infection

Virus causes hemorrhagic fever often leading to death


By Donna Ramirez | April 07, 2017

An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.

There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.

Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.

“In this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus-infected non-human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus,” said UTMB’s Thomas Geisbert, professor in the department of microbiology and immunology. “These findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic.”

The study was conducted in Biosafety Level (BSL)-4 at UTMB’s Galveston National Laboratory. BSL-4 is a highly-restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL-4 laboratory located on an American university campus.

The 2013 to 2016 Ebola virus epidemic highlighted the troubling lack of preventive or treatment options for filoviruses. Some of the therapeutics used to treat those infected with Ebola were developed and tested in the GNL.

“The level of protection observed by Dr. Geisbert’s team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible,” said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.

Other authors of this paper include UTMB’s Chad Mire, Joan Geisbert, Viktoriya Borisevich, Karla Fenton, Krystle Agans and Daniel Deer; Andrew Flyak and James Crowe, Jr. from Vanderbilt University Medical Center; Herta Steinkellner from the University of Natural Resources and Life Sciences in Vienna and Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do Kim, Michael Pauly, Jesus Velasco and Kevin Whaley.

This study was supported by the Department of Health and Human Services, National Institutes of Health and BSL-4 operations support of the Galveston National Laboratory.

Tags | Research



Social Posts

profile_image

U.S. Department of Veterans Affairs

VeteransAffairs

These Veterans are participating in the last Honor Flight Nevada trip of 2017, and it's special for many reasons.

18 mins ago
profile_image

Baylor College of Medicine

BaylorCollegeOfMedicine

Planning Thanksgiving dinner? Check out this low-calorie stuffing recipe.

29 mins ago
profile_image

BCMHouston

@bcmhouston

Planning #Thanksgiving dinner? Check out this low-calorie stuffing recipe. https://t.co/UStHceU1oY

29 mins ago
profile_image

Houston Methodist

@MethodistHosp

A new @MethodistHosp study shows that a 70-year-old malaria drug, chloroquine, can improve nanoparticle delivery to… https://t.co/huaBafq4SX

59 mins ago
profile_image

Veterans Affairs

@DeptVetAffairs

Fullerton’s 30th annual Veterans day parade and ceremony honored military Veterans https://t.co/sJ2mXIZ3gb via @thedailytitan

59 mins ago
profile_image

Veterans Affairs

@DeptVetAffairs

Hermosa Beach honors Veterans with candle lighting at Community Center https://t.co/HjgwXx14E5 via @EasyReaderNews

2 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

The first step to treating malnutrition is recognizing it. Learn about this #cancer treatment side effect:… https://t.co/U4Woc6ZzXw

2 hours ago
profile_image

Veterans Affairs

@DeptVetAffairs

Watch The American Veteran and learn how this Standup comedian got back on his feet with VA’s help and the story be… https://t.co/16zo2Uffap

3 hours ago
profile_image

Rice University

@RiceUniversity

https://t.co/LaKmtGx1YN

3 hours ago
profile_image

CHI St Luke's Health

@CHI_StLukes

Shopping this Friday? Here are four of our favorite places for a little retail therapy: https://t.co/RW9yq05XAI… https://t.co/U7qjPa1uGk

3 hours ago
profile_image

CHI St. Luke's Health

CHIStLukes

Planning on shopping this Friday? Besides our Farmers Market, here are four of our favorite places for a little retail therapy! #WeHeartTheWoodlands

3 hours ago
profile_image

U.S. Department of Veterans Affairs

VeteransAffairs

In 2011, the Make the Connection team met a remarkable military couple: Trista, a Veteran of the Army, Marine Corps, and Army National Guard; and Hector, a U.S....

4 hours ago
profile_image

BCMHouston

@bcmhouston

The Department of Neurosurgery’s Dr. Peter Kan explains how an innovative device changes the way doctors treat aneu… https://t.co/nRNUW6D2rq

4 hours ago
profile_image

Baylor College of Medicine

BaylorCollegeOfMedicine

The Department of Neurosurgery’s Dr. Peter Kan explains how an innovative device changes the way doctors treat aneurysms.

4 hours ago
profile_image

TAMU Health Sciences

@TAMHSC

Here's what you should look for the next time you're in the market for a #toothbrush: https://t.co/NL2IEmi0Sp #OralHealth

4 hours ago